Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Accenture
UBS
Johnson and Johnson
Farmers Insurance
Teva
Medtronic
US Department of Justice

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PANTOPRAZOLE SODIUM

« Back to Dashboard

Clinical Trials for Pantoprazole Sodium

Trial ID Title Status Sponsor Phase Summary
NCT00141817 Study Evaluating Pantoprazole in Children With GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.
NCT00259012 Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Nycomed Phase 3 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00259012 Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00300755 Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed Nycomed Phase 3 To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00300755 Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00312806 Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) Completed Takeda Phase 3 The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.
NCT00365300 Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Pantoprazole Sodium

Condition Name

Condition Name for Pantoprazole Sodium
Intervention Trials
Healthy 7
Gastroesophageal Reflux 7
Drug Interactions 1
Prostate Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Pantoprazole Sodium
Intervention Trials
Gastroesophageal Reflux 8
Hemorrhage 1
Duodenal Ulcer 1
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Pantoprazole Sodium

Trials by Country

Trials by Country for Pantoprazole Sodium
Location Trials
United States 111
Canada 10
India 7
Germany 4
South Africa 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Pantoprazole Sodium
Location Trials
Texas 7
Kentucky 6
New York 5
Illinois 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Pantoprazole Sodium

Clinical Trial Phase

Clinical Trial Phase for Pantoprazole Sodium
Clinical Trial Phase Trials
Phase 4 2
Phase 3 7
Phase 2 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Pantoprazole Sodium
Clinical Trial Phase Trials
Completed 19
Active, not recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Pantoprazole Sodium

Sponsor Name

Sponsor Name for Pantoprazole Sodium
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 7
Teva Pharmaceuticals USA 2
Ranbaxy Laboratories Limited 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Pantoprazole Sodium
Sponsor Trials
Industry 21
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Medtronic
Queensland Health
Farmers Insurance
UBS
Cerilliant
McKinsey
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.